<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ocriplasmin (United States and Canada: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ocriplasmin (United States and Canada: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ocriplasmin (United States and Canada: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="87799" href="/d/html/87799.html" rel="external">see "Ocriplasmin (United States and Canada: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15898399"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jetrea [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871512"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Jetrea [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15387675"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ophthalmic Agent;</li>
<li>
                        Vitreolytic</li></ul></div>
<div class="block doa drugH1Div" id="F16032069"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Jetrea has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a66f3a9f-ea4a-4d42-b64a-824d246ffcf6">Vitreomacular adhesion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitreomacular adhesion:</b> Intravitreal: 0.125 mg once (as a single dose to the affected eye).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990097"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50987406"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F16032070"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F16027538"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">5% to 20%: Ophthalmic: Intraocular inflammation (7%), decreased visual acuity (6%), blurred vision, conjunctival hemorrhage, eye pain, macular degeneration, photopsia, retinal edema, visual impairment, vitreous opacity</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;5%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hyperemia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Chromatopsia (2%; primarily described as yellowish vision), abnormal electroretinogram (a- and b-wave amplitude decrease; ≤1%), anterior chamber inflammation, cataract, conjunctival hyperemia, decreased pupillary reflex, dry eye syndrome, eye discomfort, increased intraocular pressure, iritis, macular edema, metamorphopsia, photophobia, retinal degeneration, visual disturbance (contralateral eye), vitreous detachment</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Nocturnal amblyopia, retinal detachment (pre-vitrectomy)</p></div>
<div class="block coi drugH1Div" id="F16032007"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to ocriplasmin or any component of the formulation; active or suspected ocular or periocular infections.</p></div>
<div class="block war drugH1Div" id="F16032008"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased vision: May cause decreased visual acuity as a result of condition progression with traction, which may require surgical intervention. Monitor visual acuity appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dyschromatopsia: May cause dyschromatopsia, described as yellowish vision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intravitreal injection: Intraocular inflammation, infection, hemorrhage, and/or increased intraocular pressure may result after intravitreal injection. In clinical trials, intraocular inflammation occurred at a higher rate with ocriplasmin when compared to placebo; intraocular inflammation events were typically mild and transient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lens subluxation: Administration of higher than recommended doses may result in lens subluxation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal breaks: After ocriplasmin administration, retinal detachment or retinal tear (with or without retinal detachment) may occur before, during, or after vitrectomy. Instruct patients to report symptoms suggestive of retinal detachment or endophthalmitis (eg, ocular pain, redness, photophobia, blurred/decreased vision).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Repeat administration in the same eye is not recommended. If the contralateral eye requires treatment, treatment is not recommended within 7 days of the initial injection.</p></div>
<div class="block prod-avail drugH1Div" id="F51990660"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Jetrea has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F15898400"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jetrea: 0.375 mg/0.3 mL (0.3 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F16032002"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570457"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Jetrea Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 mg/0.3 mL (per 0.3 mL): $3,555.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871513"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jetrea: 0.375 mg/0.3 mL ([DSC]); 0.5 mg/0.2 mL ([DSC])</p></div>
<div class="block adm drugH1Div" id="F16032073"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For intravitreal injection only. Must be diluted prior to use. Adequate anesthesia and a broad-spectrum antimicrobial agent should be administered prior to the procedure. Administer the diluted solution to the mid-vitreous by inserting the injection needle 3.5 to 4 mm posterior to the limbus, aiming toward the center of the vitreous cavity and avoiding the horizontal meridian. Treatment of the second eye, if needed, is not recommended within 7 days of the first injection. Repeated administration to the same eye is not recommended.</p></div>
<div class="block use drugH1Div" id="F15387659"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Vitreomacular adhesion:</b> Treatment of symptomatic vitreomacular adhesion (VMA)</p></div>
<div class="block mst drugH1Div" id="F16032001"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Jetrea: Brand name for ocriplasmin [US] may be confused with Jetrex brand name for dextromethorphan, guaifenesin, bromhexine and chlorpheniramine maleate [India]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16061141"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16061139"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F16032004"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Systemic exposure following a single intravitreal injection is expected to be low.</p></div>
<div class="block brc drugH1Div" id="F16032006"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if ocriplasmin is present in breast milk. Systemic exposure following a single intravitreal injection is expected to be low. The manufacturer recommends that caution be exercised when administering ocriplasmin to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F16032086"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Following intravitreal injection, immediately monitor for elevation in intraocular pressure, signs of endophthalmitis, retinal detachment, or decreased vision.</p></div>
<div class="block pha drugH1Div" id="F16032013"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ocriplasmin is a recombinant form of human plasmin that acts as a proteolytic within the vitreous body and vitreoretinal interface. Protein matrix components responsible for the vitreomacular adhesion (eg, laminin, fibronectin, and collagen) are lysed by ocriplasmin.</p></div>
<div class="block phk drugH1Div" id="F16032015"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Detectable levels in systemic circulation are not expected after intravitreal injection</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Endogenous protein catabolism pathway; rapidly inactivated by protease inhibitor alpha-2-antiplasmin or alpha-2-macroglobulin</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> &lt;3% of the administered dose is detected in vitreous fluid 24 hours after administration.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Jetrea (ocriplasmin) [prescribing information]. Iselin, NJ: ThromboGenics Inc; February 2017.</div>
</li>
<li>
<div class="reference">
                  Jetrea (ocriplasmin) [product monograph]. Mississauga, Ontario, Canada: Alcon Canada Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22894573">
<a name="22894573"></a>Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic Vitreolysis With Ocriplasmin for Vitreomacular Traction and Macular Holes. <i>N Engl J Med</i>. 2012;367(7):606-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ocriplasmin-united-states-and-canada-not-available-drug-information/abstract-text/22894573/pubmed" id="22894573" target="_blank">22894573</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 86876 Version 104.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
